Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV)

NCT07143968 is registered in ClinicalTrials.gov with Naga P. Chalasani as lead sponsor.

NCT NCT07143968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07143968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV)
Lead sponsor
Naga P. Chalasani
Phase
Phase 2
Overall status
Recruiting
Start date
April 23, 2026
Completion date
November 30, 2027
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hiv (human immunodeficiency virus), masld - metabolic dysfunction-associated steatotic liver disease